Nanobiotix (NBTX) Competitors $8.89 +0.51 (+6.09%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NBTX vs. JANX, EWTX, ARDX, HROW, SPRY, SDGR, AMPH, VERA, ABCL, and ETNBShould you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), Harrow (HROW), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), Amphastar Pharmaceuticals (AMPH), Vera Therapeutics (VERA), AbCellera Biologics (ABCL), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry. Nanobiotix vs. Its Competitors Janux Therapeutics Edgewise Therapeutics Ardelyx Harrow ARS Pharmaceuticals Schrodinger Amphastar Pharmaceuticals Vera Therapeutics AbCellera Biologics 89BIO Nanobiotix (NASDAQ:NBTX) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation. Which has more volatility and risk, NBTX or JANX? Nanobiotix has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.86, indicating that its share price is 186% more volatile than the S&P 500. Do institutionals & insiders believe in NBTX or JANX? 38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 29.4% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is NBTX or JANX more profitable? Nanobiotix's return on equity of 0.00% beat Janux Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NanobiotixN/A N/A N/A Janux Therapeutics N/A -11.48%-11.01% Do analysts recommend NBTX or JANX? Nanobiotix currently has a consensus price target of $8.00, indicating a potential downside of 10.76%. Janux Therapeutics has a consensus price target of $86.90, indicating a potential upside of 272.16%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanobiotix 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.08 Does the media prefer NBTX or JANX? In the previous week, Janux Therapeutics had 4 more articles in the media than Nanobiotix. MarketBeat recorded 6 mentions for Janux Therapeutics and 2 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 1.27 beat Janux Therapeutics' score of 0.92 indicating that Nanobiotix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, NBTX or JANX? Janux Therapeutics has lower revenue, but higher earnings than Nanobiotix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanobiotix$39.18M10.97-$73.73MN/AN/AJanux Therapeutics$439K3,196.34-$68.99M-$1.80-12.97 SummaryJanux Therapeutics beats Nanobiotix on 10 of the 14 factors compared between the two stocks. Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBTX vs. The Competition Export to ExcelMetricNanobiotixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$429.78M$2.48B$5.74B$9.78BDividend YieldN/A1.67%4.40%4.04%P/E RatioN/A22.5330.8326.39Price / Sales10.97506.55382.9086.63Price / CashN/A178.3537.7259.11Price / Book-5.946.2910.106.62Net Income-$73.73M$32.94M$3.26B$265.42M7 Day Performance5.10%2.27%3.90%3.58%1 Month Performance31.64%1.06%3.73%0.46%1 Year Performance74.76%5.65%37.68%19.41% Nanobiotix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBTXNanobiotix0.8002 of 5 stars$8.97+7.0%$8.00-10.8%+58.4%$429.78M$39.18M0.00100Positive NewsGap UpJANXJanux Therapeutics2.6174 of 5 stars$25.53+1.7%$91.89+259.9%-49.0%$1.51B$10.59M-14.1830EWTXEdgewise Therapeutics2.4379 of 5 stars$14.00-1.1%$41.60+197.1%-27.7%$1.49BN/A-9.0360ARDXArdelyx4.1453 of 5 stars$5.81-2.7%$11.50+97.9%-1.7%$1.44B$386.15M-25.2690News CoveragePositive NewsInsider TradeHROWHarrow3.4426 of 5 stars$38.32-1.3%$64.67+68.8%-12.8%$1.44B$199.61M-153.28180Analyst RevisionSPRYARS Pharmaceuticals2.5754 of 5 stars$14.03-3.4%$31.00+121.0%+5.2%$1.44B$89.15M-28.6390SDGRSchrodinger2.99 of 5 stars$20.05+3.5%$27.83+38.8%-5.8%$1.43B$207.54M-8.08790Positive NewsAMPHAmphastar Pharmaceuticals3.4064 of 5 stars$29.76-0.2%$31.50+5.8%-37.0%$1.39B$722.68M11.152,028News CoveragePositive NewsAnalyst ForecastVERAVera Therapeutics3.8256 of 5 stars$21.80+1.2%$63.00+189.0%-41.8%$1.37BN/A-6.0940News CoveragePositive NewsABCLAbCellera Biologics2.1645 of 5 stars$4.67+1.7%$8.00+71.3%+62.5%$1.37B$28.83M-8.49500News CoverageETNB89BIO2.2929 of 5 stars$9.44+2.3%$26.29+178.5%+0.4%$1.37BN/A-2.6140News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Janux Therapeutics Competitors Edgewise Therapeutics Competitors Ardelyx Competitors Harrow Competitors ARS Pharmaceuticals Competitors Schrodinger Competitors Amphastar Pharmaceuticals Competitors Vera Therapeutics Competitors AbCellera Biologics Competitors 89BIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBTX) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access